Genentech Pushes for Leadership in Cancer Diagnostics with Adaptive Biotechnologies Deal
By Michelle Liu
Pharma Deals Review: Vol 2019 Issue 1 (Table of Contents)
Published: 30 Jan-2019
DOI: 10.3833/pdr.v2019.i1.2399 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
In an attempt to build its immunotherapy pipeline, Genentech has agreed to collaborate with clinical stage diagnostics specialist, Adaptive Biotechnologies, to develop next-generation T-cell receptor (TCR) therapies for the treatment of a broad range of cancers...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS